Association of dyslipidemia and concomitant risk factors with in-hospital mortality in acute coronary syndrome in Switzerland: The acute myocardial infarction and unstable angina registry in Switzerland (AMIS Plus)

HeartDrug

Volumn 5, Issue 3, 2005, Pages 131-139

  Radovanovic, Dragana ^a   Erne, Paul ^b   Schilling, Julian ^a   Noseda, Giorgio ^c   Gutzwiller, Felix ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b Division of Cardiology   (Switzerland)

^c Ospedale Civico Lugano   (Switzerland)

Author keywords

Acute coronary syndrome; Dyslipidemia; Hypercholesterolemia; In hospital mortality; Risk factors

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; TICLOPIDINE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIABETES MELLITUS; DYSLIPIDEMIA; FEMALE; HEART MUSCLE ISCHEMIA; HOSPITAL ADMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PRIORITY JOURNAL; REGISTER; RISK FACTOR; SEX RATIO; STATISTICAL SIGNIFICANCE; SWITZERLAND;

EID: 20944442784     PISSN: 14229528     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085886     Document Type: Article

References (49)

1. Magnus P, Beaglehole R: The real contribution of the major risk factors to the coronary epidemics: Time to end the 'only-50%' myth. Arch Intern Med 2001;161:2657-2660.
2. Lewington S: The importance of cholesterol, blood pressure and smoking for coronary heart disease. Eur Heart J 2003;24:1703-1704.
3. Todesursachen-Statistik: Neuchâtel, Bundesamt für Statistik, 2000
4. Stamler J, Daviglus ML, Garside DB, Dyer AR, Greenland P, Neaton JD: Relationship of baseline serum cholesterol levels in 3 large cohorts of younger men to long-term coronary, cardiovascular, and all-cause mortality and to longevity. JAMA 2000;284:311-318.
5. Akosah KO, Schaper A, Cogbill C, Schoenfeld P: Preventing myocardial infarction in the young adult in the first place: How do the National Cholesterol Education Panel III guidelines perform? J Am Coll Cardiol 2003;41:1475-1479.
6. Song YM, Sung J, Kim JS: Which cholesterol level is related to the lowest mortality in a population with low mean cholesterol level: A 6.4-year follow-up study of 482,472 Korean men. Am J Epidemiol 2000;151:739-747.
7. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De Backer G, De Bacquer D, Ducimetiere P, Jousilahti P, Keil U, Njolstad I, Oganov RG, Thomsen T, Tunstall-Pedoe H, Tverdal A, Wedel H, Whincup P, Wilhelmsen L, Graham IM: Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J 2003;24:987-1003.
8. Schatz IJ, Masaki K, Yano K, Chen R, Rodriguez BL, Curb JD: Cholesterol and all-cause mortality in elderly people from the Honolulu Heart Program: A cohort study. Lancet 2001;358:351-355.
9. Chyou PH, Eaker ED: Serum cholesterol concentrations and all-cause mortality in older people. Age Ageing 2000;29:69-74.
10. Eichholzer M, Stahelin HB, Gutzwiller F, Ludin E, Bernasconi F: Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr 2000;71:569-574.
11. Onder G, Landi F, Volpato S, Fellin R, Carbonin P, Gambassi G, Bernabei R: Serum cholesterol levels and in-hospital mortality in the elderly. Am J Med 2003;115:265-271.
12. Stachon A, Boning A, Weisser H, Laczkovics A, Skipka G, Krieg M: Prognostic significance of low serum cholesterol after cardiothoracic surgery. Clin Chem 2000;46:1114-1120.
13. Jukema JW, Bruschke AV, van Boven AJ, Reiber JH, Bal ET, Zwinderman AH, Jansen H, Boerma GJ, van Rappard FM, Lie KI, et al: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 1995;91:2528-2540.
14. Herd JA, Ballantyne CM, Farmer JA, Ferguson JJ 3rd, Jones PH, West MS, Gould KL, Gotto AM Jr: Effects of fluvastatin on coronary atherosclerosis in patients with mild to moderate cholesterol elevations (Lipoprotein and Coronary Atherosclerosis Study [LCAS]). Am J Cardiol 1997;80:278-286.
15. Pfeffer MA, Sacks FM, Moye LA, Brown L, Rouleau JL, Hartley LH, Rouleau J, Grimm R, Sestier F, Wickemeyer W, et al: Cholesterol and Recurrent Events: A secondary prevention trial for normolipidemic patients. CARE Investigators. Am J Cardiol 1995;76:98C-106C.
16. Popma J, Sawyer M, Selwyn A, Kinlay S: Lipid-lowering therapy after coronary revascularization. Am J Cardiol 2000;86:18H-28H.
17. Tonkin A, Colquhoun D, Emberson J, Hague W, Keech A, Lane G, MacMahon S, Shaw J, Simes R, Thompson P, White H, Hunt D: Effects of pravastatin in 3,260 patients with unstable angina: Results from the LIPID study. Lancet 2000;356:1871-1875.
18. Majumdar S, Gurwitz J, Soumerai S: Undertreatment of hyperlipidemia in the secondary prevention of coronary artery disease. J Gen Intern Med 1999;14:711-717.
19. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: The MIRACL study: A randomized controlled trial. JAMA 2001;285:1711-1718.
20. Muntwyler J, Amann F, Gutzwiller F, Follath F: Lipid-lowering therapy in patients with coronary artery disease: Proportion of patients requiring treatment according to recommendations of the Swiss Society of Cardiology (in German). Schweiz Med Wochenschr 1999;129:1959-1963.
21. Van de Werf F, Ardissino D, Betriu A, Cokkinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verbeugt FW, Wijns W: Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2003;24:28-66.
22. Bertrand ME, Simoons ML, Fox KA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002;23:1809-1840.
23. Erne P, Radovanovic D, Urban P, Stauffer J-C, Bertel O, Gutzwiller F, for the AMIS Plus Investigators: Early drug therapy and in-hospital mortality following acute myocardial infarction. Heart Drug 2003;3:134-140.
24. Trevelyan J, Needham EW, Smith SC, Mattu RK: Sources of diagnostic inaccuracy of conventional versus new diagnostic criteria for myocardial infarction in an unselected UK population with suspected cardiac chest pain, and investigation of independent prognostic variables. Heart 2003;89:1406-1410.
25. Schnohr P, Jensen JS, Scharling H, Nordestgaard BG: Coronary heart disease risk factors ranked by importance for the individual and community. A 21 year follow-up of 12 000 men and women from The Copenhagen City Heart Study. Eur Heart J 2002;23:620-626.
26. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S: Predictive accuracy of the Framingham coronary risk score in British men: Prospective cohort study. BMJ 2003;327:1267.
27. Hense HW, Schulte H, Lowel H, Assmann G, Keil U: Framingham risk function overestimates risk of coronary heart disease in men and women from Germany - Results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 2003;24:937-945.
28. Empana JP, Ducimetiere P, Arveiler D, Ferneres J, Evans A, Ruidavets JB, Haas B, Yarnell J, Bingham A, Amouyel P, Dallongeville J: Are the Framingham and PROCAM coronary heart disease risk functions applicable to different European populations? The PRIME Study. Eur Heart J 2003;24:1903-1911.
29. Hasdai D, Behar S, Wallentin L, Danchin N, Gitt A, Boersma E, Fioretti P, Simoons M, Battler A: A prospective survey of the characteristics, treatments and outcomes of patients with acute coronary syndromes in Europe and the Mediterranean basin; the Euro Heart Survey of Acute Coronary Syndromes (Euro Heart Survey ACS). Eur Heart J 2002;23:1190-1201.
30. Lefkowitz RJ, Willerson JT: Prospects for cardiovascular research. JAMA 2001;285:581-587.
31. Emberson JR, Whincup PH, Morris RW, Walker M: Re-assessing the contribution of serum total cholesterol, blood pressure and cigarette smoking to the aetiology of coronary heart disease: Impact of regression dilution bias. Eur Heart J 2003;24:1719-1726.
32. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB: Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-1847.
33. Stamler J, Wentworth D, Neaton JD: Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-2828.
34. Heidrich J, Wellmann J, Hense H-W, Siebert W, Liese AD, Löwel H, Keil U: Classical risk factors for myocardial infarction and total mortality in the community -13-year follow-up of the MONICA Augsburg cohort study. Z Kardiol 2003;92:445-454.
35. Lindqvist P, Bengtsson C, Lissner L, Bjorkelund C: Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age. J Intern Med 2002;251:484-489.
36. Lowe LP, Greenland P, Ruth KJ, Dyer AR, Stamler R, Stander J: Impact of major cardiovascular disease risk factors, particularly in combination, on 22-year mortality in women and men. Arch Intern Med 1998;158:2007-2014.
37. Brescianini S, Maggi S, Farchi G, Mariotti S, Di Carlo A, Baldereschi M, Inzitari D: Low total cholesterol and increased risk of dying: Are low levels clinical warning signs in the elderly? Results from the Italian Longitudinal Study on Aging. J Am Geriatr Soc 2003;51:991-996.
38. Horwich TB, Hamilton MA, Maclellan WR, Fonarow GC: Low serum total cholesterol is associated with marked increase in mortality in advanced heart failure. J Card Fail 2002;8:216-224.
39. Shestov DB, Deev AD, Klimov AN, Davis CE, Tyroler HA: Increased risk of coronary heart disease death in men with low total and low-density lipoprotein cholesterol in the Russian Lipid Research Clinics Prevalence Follow-up Study. Circulation 1993;88:846-853.
40. Stemmermann GN, Chyou PH, Kagan A, Nomura AM, Yano K: Serum cholesterol and mortality among Japanese-American men. The Honolulu (Hawaii) Heart Program. Arch Intern Med 1991;151:969-972.
41. Frank JW, Reed DM, Grove JS, Benfante R: Will lowering population levels of serum cholesterol affect total mortality? Expectations from the Honolulu Heart Program. J Clin Epidemiol 1992;45:333-346.
42. Becker RC, Corrao JM, Lew R, Bradley J, Queenan J: Relationship between serum total cholesterol, infarct size, and early clinical outcome following acute myocardial infarction. Cardiology 1992;80:65-70.
43. Ahnve S, Angelin B, Edhag O, Berglund L: Early determination of serum lipids and apolipoproteins in acute myocardial infarction: Possibility for immediate intervention. J Intern Med 1989;226:297-301.
44. Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A: Management of acute coronary syndromes. Variations in practice and outcome; Findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002;23:1177-1189.
45. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROAS-PIRE II Euro Heart Survey Programme. Eur Heart J 2001;22:554-572.
46. Aronow H, Topol E, Roe M, Houghtaling P, Wolski K, Lincoff A, Harrington R, Califf R, Ohman E, Kleiman N, Keltai M, Wilcox R, Vahanian A, Armstrong P, Lauer M: Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001;357:1063-1068.
47. Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, Karas RH: Effects of statins on nonlipid serum markers associated with cardiovascular disease: A systematic review. Ann Intern Med 2003;139:670-682.
48. Pourati I, Kimmelstiel C, Rand W, Karas RH: Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J 2003;146:876-881.
49. Attebring M, Hartford M, Berndt A, Herlitz J: Has interest in secondary prevention increased among physicians after the 4S study? Scand Cardiovasc J 2000;34:164-167.